Jalra

Vildagliptin, the active ingredient in Jalra, is a DPP-4 inhibitor presented as a tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Jalra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jalra (vildagliptin) is indicated for the management of type 2 diabetes mellitus, a condition characterized by impaired insulin secretion and increased glucagon production.

- Type 2 diabetes mellitus: improves blood glucose control by enhancing insulin release and reducing glucagon. - Monotherapy in type 2 diabetes: lowers HbA1c when used alone alongside diet and exercise. - Combination therapy with metformin: provides additional reduction in fasting plasma glucose and HbA1c.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Headache: transient cranial pain. - Dizziness: occasional light‑headedness. - Upper respiratory tract infection: nasopharyngitis or mild cough. - Hypoglycemia (when combined with sulfonylureas or insulin): low blood sugar episodes.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or hepatitis. - Bullous skin disorders: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Severe hypoglycemia: prolonged low glucose requiring assistance.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Renal function: assess creatinine clearance and adjust dose in impairment. - Hepatic function: evaluate liver enzymes prior to use. - Pancreatitis risk: discontinue if severe abdominal pain occurs. - Concomitant sulfonylureas or insulin: monitor blood glucose closely to avoid hypoglycemia. - Elderly patients: start at lower dose and titrate cautiously. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Vildagliptin may interact with several co‑administered medicines, requiring clinical awareness.

Major Interactions (Avoid): - Other DPP‑4 inhibitors: additive inhibition may increase risk of adverse effects. - Insulin or sulfonylureas: heightened risk of severe hypoglycemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal function, especially in patients with existing renal impairment. - Diuretics: monitor electrolytes and renal parameters. - ACE inhibitors or ARBs: watch for changes in blood pressure and renal function. - Warfarin: occasional reports of altered INR, require periodic monitoring.